STOCK TITAN

iSpecimen to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference on September 13-15, 2021

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

iSpecimen (Nasdaq: ISPC), a leader in the online marketplace for human biospecimens, announced CEO Christopher Ianelli will participate in the H.C. Wainwright 23rd Annual Global Investment Conference, occurring virtually from September 13-15, 2021. His presentation will be available on-demand starting September 13 at 7:00 a.m. ET. iSpecimen connects life scientists with healthcare providers through its innovative platform to facilitate medical discovery.

Positive
  • None.
Negative
  • None.

LEXINGTON, Mass., Sept. 1, 2021 /PRNewswire/ -- iSpecimen Inc. (Nasdaq: ISPC) ("iSpecimen" or the "Company"), an online marketplace for human biospecimens, today announced that Christopher Ianelli, MD, PhD, CEO and President of iSpecimen, will participate in the H.C. Wainwright 23rd Annual Global Investment Conference to be held virtually on September 13-15, 2021. Dr. Ianelli's corporate presentation will be available on-demand starting Monday, September 13, 2021 at 7:00 a.m. ET.

For more information about the H.C. Wainwright conference, or to schedule a one-on-one meeting with iSpecimen's management, please contact your H.C. Wainwright representative directly or KCSA Strategic Communications at iSpecimen@kcsa.com

About iSpecimen
iSpecimen offers an online marketplace for human biospecimens, connecting life scientists in commercial and non-profit organizations with healthcare providers that have access to patients and specimens needed for medical discovery. Proprietary, cloud-based technology enables scientists to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers, and other healthcare organizations. For more information about iSpecimen, please visit www.ispecimen.com.

Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are characterized by future or conditional verbs such as "may," "will," "expect," "intend," "anticipate," believe," "estimate" and "continue" or similar words. You should read statements that contain these words carefully because they discuss future expectations and plans, which contain projections of future results of operations or financial condition or state other forward-looking information.

Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to the risks factors contained in the Company's filings with the Securities and Exchange Commission, which are available for review at www.sec.gov. Forward-looking statements speak only as of the date they are made. New risks and uncertainties arise over time, and it is not possible for the Company to predict those events or how they may affect the Company. If a change to the events and circumstances reflected in the Company's forward-looking statements occurs, the Company's business, financial condition and operating results may vary materially from those expressed in the Company's forward-looking statements. Readers are cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

For further information, please contact:

Investor Contact
KCSA Strategic Communications
Allison Soss / Scott Eckstein
iSpecimen@kcsa.com

Media Contact
Kaitlynn Cooney
For iSpecimen
kcooney@brodeur.com 
609.351.5944

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/ispecimen-to-participate-in-the-hc-wainwright-23rd-annual-global-investment-conference-on-september-13-15-2021-301366649.html

SOURCE iSpecimen Inc.

FAQ

What event will iSpecimen participate in?

iSpecimen will participate in the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021.

Who is presenting for iSpecimen at the conference?

Christopher Ianelli, CEO and President of iSpecimen, will present at the conference.

When will iSpecimen's presentation be available?

iSpecimen's presentation will be available on-demand starting September 13, 2021, at 7:00 a.m. ET.

What is iSpecimen's business model?

iSpecimen operates an online marketplace for human biospecimens, connecting scientists with healthcare providers for medical research.

How can investors contact iSpecimen for more information?

Investors can contact KCSA Strategic Communications at iSpecimen@kcsa.com for more information.

iSpecimen Inc.

NASDAQ:ISPC

ISPC Rankings

ISPC Latest News

ISPC Stock Data

3.30M
823.02k
14.5%
4.04%
7.79%
Diagnostics & Research
Services-commercial Physical & Biological Research
Link
United States of America
WOBURN